Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis
Nicola Capasso, Agostino Nozzolillo, Giulia Scalia, Roberta Lanzillo, Antonio Carotenuto, Marcello De Angelis, Martina Petruzzo, Francesco Saccà, Cinzia Valeria Russo, Vincenzo Brescia Morra, Marcello Moccia
Topics & Concepts
OcrelizumabMedicineRituximabMultiple sclerosisCD20CD8CD19ImmunologyLymphocyteInternal medicineFlow cytometryAntibodyAntigenMultiple Sclerosis Research StudiesImmunotherapy and Immune ResponsesPolyomavirus and related diseases